Alveus Therapeutics branding and website
Alveus Therapeutics develops groundbreaking therapies to improve long-term weight management and tolerability in obese adults. Stoere Binken Design creates an innovative vision that forms the starting point for a brand identity radiating strength, trust, and progress – from logo to digital experience.
Clients and business partners give us a 5,0 Google Review ★★★★★
From AI experiment to brand identity
In an era where AI logo generators are popping up everywhere, many startups opt for a quick visual start. But what is often missing is a logo that supports the brand’s growth, vision, and identity in the long term.
This was also the case with Alveus Therapeutics. The original logo (generated by ChatGPT) did not meet the brand’s ambitions.
Stoere Binken Design developed a redesign of the AI logo – respecting the core and professionally translating it into sustainable branding. In multiple design rounds, we analyzed the logo, reduced it to its essence, rebuilt it, and refined it into a strong and future-proof brand image.
Typographic refinement
The typography has been specifically refined in the design of the letters ‘A’ and ‘l’:
- For the A, the originally straight styles have been subtly curved so that the letter shape aligns better with the curved contours of the visual mark and creates more formal coherence within the logo system.
- The l has been given a rounded foot, which visually softens the letter spacing and gives the wordmark a more human, less mechanical appearance.
Onze logo's
Bold dark-mode website
The dark-mode website of Alveus Therapeutics translates the renewed brand image into a powerful digital experience. The carefully curated, contemporary color palette supports the high-tech look and clearly positions the brand as an innovative player within the biotech sector.
The dark User Interface (UI) not only creates a modern, high-tech look but also emphasizes clarity, contrast, and trust—essential values within a sector where precision and credibility are central. In this way, the web design translates the brand strategy into a compelling online presentation that makes an impact on the target audience.
Onze websites
About Alveus Therapeutics
ALV-100
Alveus is developing a portfolio of novel therapies targeting metabolic diseases. Significant unmet needs remain in the field of obesity, particularly regarding achieving sustainable weight loss and addressing the key underlying pathologies that affect cardiometabolic health.
In doing so, Alveus aims to address these crucial issues and realize meaningful improvements in patient outcomes.
ALV-100 – a fusion protein of a GIPR antagonist and a GLP-1R agonist – is a novel approach validated by human genetic research. This research demonstrates that loss-of-function GIPR variants are associated with a lower BMI and improved cardiometabolic characteristics. It is designed to leverage the synergistic effects of these mechanisms for sustainable weight loss, resulting in a lower treatment burden for patients.
Amylin small molecule
In addition to the main program, they are developing a Pipeline of amylins with highly distinctive small molecules, peptides, and novel formats for various indications.